Menu
Submit Data
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Back to Studies

Thymogen

Glu-Trp, EW dipeptide, Oglufanide, L-Glutamyl-L-tryptophan

Quick Stats
Studies 94
Trials 51
Overview Studies Clinical Trials
Score 2
2006 pubmed

[Decision on the immunomodulating therapy in unspecific osteomyelitis of the spine].

Vishnevskiĭ. A A AA; Orlov. A B AB; Tikhodeev. S A SA

View Original Source

Key Findings

  • Immunomodulating therapy, including thymogen, was used in 54 patients with unspecific osteomyelitis of the spine.
  • Most patients showed a deficit in the T‑cell arm of immunity, leading the authors to recommend T‑cell‑targeting peptides such as thymogen.
  • The authors argue that immune correction should be a standard part of treatment for spinal infections, tailored to the specific immune impairment.

Practical Outcomes

  • For biohackers interested in immune support, the study hints that thymogen may be useful when T‑cell function is low, but the evidence is limited to a specific infection setting. It does not provide dosage details or safety data for healthy individuals, so any self‑experimentation should be approached cautiously and preferably under medical supervision.

Summary

A small clinical study of 54 patients with spinal bone infection found that adding immune‑boosting drugs like thymogen (a thymus‑derived peptide) helped when the patients had weak T‑cell immunity. The authors suggest that checking which part of the immune system is impaired and then using the right peptide or cytokine could improve outcomes.

Abstract

Immunomodulating therapy was used in treatment of 54 patients with unspecific osteomyelitis of the spine (UOS). The age of the patients was from 15 through 76 years. The authors consider that immunocorrection should be included in the complex of obligatory measures of treatment of patients with purulent infections of the spine and is dependent on the type of immunological impairments. For its success it is necessary to determine the type and degree of immunity impairment. Since in most cases of UOS there is a disorder in the T-cell link of immunity, it is preferable to use cytomedins (T-activin, thymalin, thymogen etc) or cytokines (e.g. roncoleukin). In cases of an insufficient B-cell link the medicines of choice are licopid and myelopid.

Study Information

Provider

pubmed

Year

2006